[go: up one dir, main page]

TN2009000491A1 - Use of heterosidic flavonoid derivatives for therapy of stem cell cancers - Google Patents

Use of heterosidic flavonoid derivatives for therapy of stem cell cancers

Info

Publication number
TN2009000491A1
TN2009000491A1 TNP2009000491A TN2009000491A TN2009000491A1 TN 2009000491 A1 TN2009000491 A1 TN 2009000491A1 TN P2009000491 A TNP2009000491 A TN P2009000491A TN 2009000491 A TN2009000491 A TN 2009000491A TN 2009000491 A1 TN2009000491 A1 TN 2009000491A1
Authority
TN
Tunisia
Prior art keywords
stem cell
heterosidic
therapy
flavonoid derivatives
cell cancers
Prior art date
Application number
TNP2009000491A
Other languages
French (fr)
Inventor
Bourogaa Ezzeddine
Despeaux Mathieu
Mezghani-Jarraya Raoudha
Fabre Nicolas
Bertrand Jessica
Payrastre Laurence
Demur Cecile
Jacques Fournie Jean
Racaud Sultan Claire
El Feki Abdelfattah
Damak Mohamed
Original Assignee
Inst Nat Sante Rech Med
Chimie Des Substances Naturelles Lab De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Chimie Des Substances Naturelles Lab De filed Critical Inst Nat Sante Rech Med
Priority to TNP2009000491A priority Critical patent/TN2009000491A1/en
Publication of TN2009000491A1 publication Critical patent/TN2009000491A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to therapy of stem cell cancer and more specifically against acute myeloid leukaemia. The present invention more precisely deals with the use of heterosidic flavonoid derivatives and in particular rutin, or derivatives thereof for the treatment of stem cell cancer specifically acute myeloid leukaemia, for preventing tumor relapse in a patient and/or for preventing solid tumor metastasis in a patient.
TNP2009000491A 2009-11-23 2009-11-23 Use of heterosidic flavonoid derivatives for therapy of stem cell cancers TN2009000491A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TNP2009000491A TN2009000491A1 (en) 2009-11-23 2009-11-23 Use of heterosidic flavonoid derivatives for therapy of stem cell cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TNP2009000491A TN2009000491A1 (en) 2009-11-23 2009-11-23 Use of heterosidic flavonoid derivatives for therapy of stem cell cancers

Publications (1)

Publication Number Publication Date
TN2009000491A1 true TN2009000491A1 (en) 2011-03-31

Family

ID=54695937

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000491A TN2009000491A1 (en) 2009-11-23 2009-11-23 Use of heterosidic flavonoid derivatives for therapy of stem cell cancers

Country Status (1)

Country Link
TN (1) TN2009000491A1 (en)

Similar Documents

Publication Publication Date Title
MX2010006991A (en) Therapeutic cancer treatments.
PH12012501782A1 (en) Phytocannabinoids in the treatment of cancer
EA200901074A1 (en) TREATMENT OF THE METASTATIC STAGE OF PROSTATE CANCER WITH DEGARELIX
MX2011008221A (en) Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor.
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
MX2010003815A (en) Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2013006392A (en) Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2015007185A (en) Use of eribulin in the treatment of breast cancer.
UA108618C2 (en) APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
WO2010003520A3 (en) Anti-tumor immunotherapy
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
MX342250B (en) Methods of treating cancer using notch antagonists.
TW201611831A (en) Novel antitumoral use of CABAZITAXEL
MX2012001783A (en) Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone.
UA117663C2 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX336761B (en) Compounds for treatment of cancer.
EA201200190A1 (en) FULVESTRANT IN DOSE 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER
AP2012006181A0 (en) Targeting PAX2 for the treatment of breast cancer.
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
TN2009000491A1 (en) Use of heterosidic flavonoid derivatives for therapy of stem cell cancers
MX2012003287A (en) Use of the sparc microenvironment signature in the treatment of cancer.